Related Experiment Video

Updated: May 19, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Targeted agents and systemic therapy in hepatocellular carcinoma

Celina Ang1, Eileen M O'Reilly, Ghassan K Abou-Alfa

  • 1Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|September 4, 2012
PubMed

Insights

Targeted therapies show promise for advanced hepatocellular cancer (HCC) treatment. Further research into molecular pathways and novel agents aims to improve patient outcomes and survival benefits.

Area of Science:

  • Oncology
  • Molecular Biology
  • Hepatology

Background:

  • Hepatocellular cancer (HCC) has shown limited response to traditional treatments like chemotherapy and immunotherapy.
  • Molecular insights into HCC pathogenesis reveal aberrant signaling pathways crucial for targeted therapy development.

Purpose of the Study:

  • To explore the potential of novel targeted agents in improving outcomes for advanced hepatocellular cancer (HCC) patients.
  • To investigate the role of specific molecular pathways in hepatocarcinogenesis and response to therapy.

Main Methods:

  • Review of current literature on targeted therapies for HCC.
  • Analysis of molecular pathogenesis and signaling pathways implicated in HCC.
  • Evaluation of clinical data for agents like sorafenib.

Main Results:

  • Targeted agents, such as the Raf kinase inhibitor sorafenib, have demonstrated clinically meaningful survival benefits in advanced HCC.
  • Identification of aberrant signaling pathways provides a basis for developing new therapeutic strategies.

Conclusions:

  • Targeted therapy represents a promising approach for managing advanced hepatocellular cancer (HCC).
  • Continued development and evaluation of targeted agents, alongside a deeper understanding of disease biology, are essential for improving HCC patient outcomes.

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...